Navigation Links
ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
Date:2/23/2009

LEUVEN, Belgium and LUND, Sweden, February 23 /PRNewswire-FirstCall/ --

- Trial to Assess the Benefits of Partial Factor VIII Inhibition in Patients Undergoing Knee Replacement Surgery

ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International (OMXS: BINV) announce today that the first patient has been enrolled in the Phase II trial with their long-acting anticoagulant TB-402 for the prophylaxis of Deep Vein Thrombosis (DVT) following orthopaedic surgery. TB-402, which is given as a single injection post surgery, could overcome the major drawbacks such as bleeding and the need for extensive patient monitoring associated with current anti-coagulant therapy.

TB-402 is a recombinant human monoclonal antibody that targets Factor VIII, a key component of the coagulation cascade. TB-402 is a novel anticoagulant agent, which may deliver important clinical benefits due to it only partially inhibiting Factor VIII activity even when given in very high doses. This novel mode of action is expected to reduce the risk of undesirable bleeding events and the need for patient monitoring, the two main drawbacks associated with current anticoagulants. In addition, TB-402 is a long-acting agent which means that patients are expected to receive just one single dose after surgery to prevent the development of DVT, as opposed to all current treatment options which require daily treatment for up to several weeks.

The Phase II trial is an active (enoxaparin)-controlled, dose-escalating, multicenter, prospective, randomised, open label trial evaluating TB-402 for the prophylaxis of DVT after knee surgery. The study will assess three different doses of TB-402 given as a single intravenous bolus injection post knee replacement surgery. The trial will enrol 300 patients across 36 centers mainly in Central Europe. The primary endpoint is the safety and efficacy of the three
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ThromboGenics N.V.: Business Update
2. ThromboGenics Announces Half Year Results 2008
3. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
4. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
5. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
6. ThromboGenics N.V. - Business Update
7. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
10. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
11. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today ... of three large odour control systems for waste water treatment ... orders are consistent with the market resurgence in ... and CEO. "After a difficult period of restraint in our ... see sales growth. Our lower cost structure, technology improvements and ...
(Date:9/2/2014)... Melbourne, Victoria, Australia (PRWEB) September 02, 2014 ... may provide a cure for chronic tinnitus are seeking ... campaign, run on the Indiegogo platform ( http://igg.me/at/tinaway ), ... designed to be a therapeutic ‘mHealth’ app and is ... the brainchild of a team of biomedical and software ...
(Date:8/31/2014)... Wockhardt Limited today announces a major boost ... when two of its drugs, WCK 771 and WCK ... status from U.S. Food & Drug Administration (FDA).  QIDP ... which have a high degree of unmet need in ... Control (a top U.S. government health and safety body). ...
(Date:8/30/2014)... The Global and China Electrical ... study on the current state of the Electrical ... The report provides a basic overview of the ... Global market analysis and Chinese domestic market analysis ... trends and competitive landscape of the market. A ...
Breaking Biology Technology:tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 2tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 3tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 4tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 5U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 2Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 3
... /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. ("Angiotech") (NASDAQ: ... and medical device company, today announced that ... (the "Tender Offer"),for its outstanding Senior Floating ... "First Priority Notes"), and its outstanding 7.75% ...
... breadth of experience and business expertise, SCOTTSDALE, ... technology company that markets the Provant(R) Wound Therapy,System, ... its Board of,Directors. The two new directors are ... and Charles "Chuck" S. Lunden, a principal with,Bederson ...
... ... the job done, NEWARK, N.J., Aug. 22 BioNeutral announced ... its,Ogiene(TM) FE technology to bring 10,000 mobile homes into full compliance,so ... in need,of biohazard-free housing., Dr. Andy Kielbania, Chief Scientist at ...
Cached Biology Technology:Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014 2Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014 3Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014 4Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014 5Regenesis Biomedical Announces Additions to Board of Directors 2BioNeutral Signs Agreement With a Non-profit for Long-Term Removal of Formaldehyde to Save 10,000 Mobile Homes in Louisiana 2
(Date:9/1/2014)... MA ─ Dietary quality in the U.S. has improved ... trans fat intakebut overall dietary quality remains poor and ... according to a new study from Harvard School of ... direct evidence to date that the extensive efforts by ... are having some payoff, but it also indicates that ...
(Date:9/1/2014)... BOSTON (September 1, 2014, 10:20 AM EDT) It ... healthy low-calorie foods over unhealthy higher-calorie foods, according to ... Human Nutrition Research Center on Aging (USDA HNRCA) at ... today in the journal Nutrition & Diabetes , ... suggests that it is possible to reverse the addictive ...
(Date:9/1/2014)... the Nomenclature Section of the XVIII International Botanical Congress ... meeting is held every six years and it is ... naming algae, fungi and plants get together to debate ... they study. This is the primary product of the ... and plants, which was published in 2012. The other ...
Breaking Biology News(10 mins):Quality of US diet shows modest improvement, but overall remains poor 2Quality of US diet shows modest improvement, but overall remains poor 3Training your brain to prefer healthy foods 2Week-long meeting on naming algae, fungi, and plants recorded for posterity 2
... new study finds that Caribbean seaweeds are far better competitors ... this triumph is bad news for Caribbean coral reefs. ... the living corals that build reefs and contribute startling white ... environment but in fact a battle is constantly waged between ...
... Obama has made cyber security an integral issue when ... ensure that the U.S. remains on the cutting edge, ... will convene a gathering of the nation,s top minds ... issues affecting the economy and United States, national security. ...
... Smith, Ph.D., Wellcome Trust Principal Research Fellow and ... Fellow of Emmanuel College, Cambridge, has been bestowed ... Award, recognizing exemplary leadership in the international microbiological ... University of Virginia, says Smith is "internationally recognized ...
Cached Biology News:Jim Demitrieus, CEO of EyeLock, Invited to White House Cyber Security Event 2Jim Demitrieus, CEO of EyeLock, Invited to White House Cyber Security Event 3The American Society for Microbiology honors Geoffrey L. Smith 2
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
...
...
Biology Products: